SANOFI A global healthcare leader, focused on patients’ … contents corporate presentation 2014 2 sanofi at a glance our growth platforms innovation in r&d our responsibility key

CORPORATE PRESENTATION

2014

SANOFI

A global

healthcare

leader,

focused

on patients’

needs

CONTENTS

CORPORATE PRESENTATION 2014 2

SANOFI AT A GLANCE

OUR GROWTH PLATFORMS

INNOVATION IN R&D

OUR RESPONSIBILITY

KEY FIGURES


SANOFI AT A GLANCE


OUR HERITAGE

SANOFI AT A GLANCE

Hoechst Marion

Roussel 1997

Roussel 1911

Marion 1950

Hoechst 1863

Synthélabo 1970

Delalande 1924

Delagrange 1931

Robert & Carrière

1901

Dausse 1834

BMP Sunstone, Medley, Merial, Nepentes, Zentiva,

Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha

Biotechnics 2008-2010

Genzyme 2011

Sanofi-aventis 2004

Aventis 1999

Sanofi-Synthélabo 1999

Sanofi Pasteur 2004

Sterling 1901

Midy 1718

Clin Midy 1971

Chinoin 1919

Sanofi 1973

Connaught 1922

Rorer 1910

Rhône-Poulenc Rorer 1990

Institut Mérieux

1897

Wittman & Poulenc

1860

A long tradition in health


Information of December 31st 2013

OUR GROUP

SANOFI AT A GLANCE

We are a global

healthcare company

engaged in the

research, development,

manufacturing and

marketing of healthcare

solutions. present in more than

100 countries

more than

110 000 employees

A diversified offer

of pharmaceuticals,

vaccines and innovative

therapeutic solutions

112 Industrial sites in 41 countries

R&D A major biopharmacy

player

• 45% of revenues

generated by biologics

• 80% of development

projects are biologics

€33 bn*

In sales in 2013

* €32,951 M

OUR COMMITMENT AND OUR AMBITION

SANOFI AT A GLANCE


We act with our partners to protect health,

enhance life, provide hope and respond to

the potential healthcare needs of 7 billion

people around the world.

With our global footprint and commitment

to improving access to medicines

and healthcare, we work tirelessly to

make a difference to people’s lives every

day and transform scientific innovations

into therapeutic solutions for patients.

BRING INNOVATIVE PRODUCTS TO MARKET

SEIZE VALUE-ENHANCING GROWTH OPPORTUNITIES

ADAPT STRUCTURE FOR FUTURE CHALLENGES & OPPORTUNITIES


DELIVER SUSTAINABLE LONG-TERM GROWTH

SANOFI AT A GLANCE OUR STRATEGY

GROW A GLOBAL HEALTHCARE LEADER WITH SYNERGISTIC PLATFORMS

CORPORATE PRESENTATION 2014 8 8




Diabetes solutions

Emerging markets

Vaccines

Consumer Healthcare

Animal Health

Genzyme

Other Innovative Products


The strong presence of Sanofi in Emerging Markets supports access to health by proposing a wide range of medicines at adapted prices.

EMERGING MARKETS

Latin America Asia Africa & Middle East Eastern Europe Russia Turkey


(1) IMS Health (IMS Midas 2013)

1st Healthcare Company

in Emerging Markets

in 2013(1)

(1) IMS MIDAS MAT 03/2013



DIABETES SOLUTIONS

TODAY Lantus®

#1 worldwide

in insulins(2)

TOMORROW

Source: IDF Diabetes Atlas Sixth Edition,

International Diabetes Federation

By 2030, it is anticipated million people

552

New insulin U300(5) (1)IMS sales 2013

(2)IMS sales 2013

(3)Marketing Authorization granted in Europe February 2013

(4)Launched in India September 2012

(5) U300 is an investigational new formulation of insulin glargine.

Today million people(1)

have diabetes worldwide.

382 Comprehensive

offering of therapies

(3)

(4)

Patient friendly

delivery pens

Intelligent Blood

Glucose Monitoring

devices

Hexaxim®

(in emerging

countries)



HUMAN VACCINES

TOMORROW

TODAY

A leadership position with Sanofi Pasteur

1bn doses of vaccines

to immunize more than 500 million

people

infectious diseases

20 vaccines for

A NEW WAVE OF INNOVATION being prepared with vaccines against dengue and infections of Clostridium Difficile (nosocomial infections)

Feminine care: Lactacyd®


Solutions to manage health in the

everyday life all around the world.

With a diversified brands

portfolio based on consumer

insights-driven innovation.

Pain: Doliprane® No Spa®

Dorflex® Icy Hot®

Gastro-intestinal: Maalox® Rolaids®

Essentiale® Enterogermina®

Allergy: Allegra® Nasacort®

Top 3 Global player in

Consumer Healthcare(1)

(1) IMS MAT Sept 2013,

Nicholas Hall & Company

Cough, cold

and sore throat: Rhinathiol® Bronchicum®

Haowawa®

VMS (vitamins

and mineral

supplements):

Cenovis® Nature’s Own®

Magné Vie®


CONSUMER HEALTHCARE

World-leading,

innovation-driven

animal health

company, providing

a comprehensive

range of products

to enhance the

health, well-being

and performance

of a wide range of

animals.


COMPANION ANIMALS

PARVORUVAX Swin

Ruminant

PRODUCTION ANIMALS

Horses

Avian AVINEW

#1 # 2 companion

animal

avian

vaccines

Dogs&Cats


ANIMAL HEALTH: MERIAL

Gaucher disease

Pompe disease

Fabry disease



GENZYME: RARE DISEASES AND MULTIPLE SCLEROSIS

TODAY

RARE DISEASES RARE DISEASES

TOMORROW

MULTIPLE SCLEROSIS

7,000 rare diseases identified

worldwide of which

400 have a treatment

Gaucher disease

Homozygous familial

Hypercholesterolemia

Mucopolysaccharidosis

Type I

Colorectal cancer

OTHER INNOVATIVE PRODUCTS



Atrial fibrillation

ANTIARRYTHMIC

Hematopoietic cancer

Prostate cancer

ONCOLOGY

ALLERGY


INNOVATION IN R&D

• Multiple Sclerosis

• Diabetes

• Oncology

• Rare Diseases

• Cardio-Metabolic Diseases

• Immunology

• Vaccines


We have to be where the diseases and the patients’ needs are.

We act as one to discover and develop therapies that prevent, treat and cure disease.

9

projects and vaccines in clinical development

high potential projects in late

stage development

49

INNOVATION IN R&D

ACCELERATE INNOVATION FOR PATIENTS

Our main areas of research include:


This health ecosystem places the patient and their needs at the heart of the priorities.

Translational Medicine to create deeper interaction between clinic and fundamental research and improve diagnosis and patient care.

INNOVATION IN R&D

ACCELERATE INNOVATION FOR PATIENTS

Open innovation

VENTURE CAPITAL

HOSPITALS

GOVERNMENT BIOPHARMA

PATIENTS

PATIENTS

NEEDS

UNIVERSITIES

TECH

Biotechnology partnerships to accelerate innovation.

80% of our development

projects are biologics(1)

(1) 39 new molecular entities and vaccines of a total of 49 (source: Sanofi annual results 2013)

20

Diabetes • U300

• Lixisenatide

• LixiLan

Atopic dermatitis

and asthma

• Dupilumab

• Alirocumab

Hypercholesterolemia

• Sarilumab

Rheumatoid arthritis

INNOVATION IN R&D

STRENGTHENED

AND INNOVATIVE

PORTFOLIO FOR

PATIENTS

Human Vaccines • 6-in-1 vaccine PR51

• Dengue vaccine

• Clostridum Difficile vaccine

Product launches

between

2014 and 2018

High potential 9

(source: Sanofi annual results 2013)



OUR RESPONSIBILITY

Improve access to medicines by promoting

comprehensive management of diseases

combining prevention, diagnosis and treatment

in developing countries.

reduce health inequalities

through its ’programs dedicated to:

Childhood Cancer, Maternal and Neonatal Mortality

and access to healthcare for the world’s poorest

populations.

Promoting quality care by fighting against

counterfeit medicines.

More than

1/3 of the population

have no access

to healthcare.


OUR RESPONSIBILITY

ACCESS TO QUALITY HEALTHCARE FOR ALL

To “move further” the human

right to health becomes

a reality, Sanofi develops

programs to improve access

to medicines for people

in developing countries.

The main

disease areas

for Access

to Medicines


Approach • Information and education

• Medicines adapted to patients needs

• Tiered pricing policy

• R&D program for therapeutic innovation

• Industrial expertise

OUR RESPONSIBILITY

IMPROVE ACCESS TO MEDICINES

•Malaria •Tuberculosis •Neglected Tropical Diseases (Sleeping

sickness, Leishmaniasis…)

•Mental health •Epilepsy

and vaccine Preventable diseases

years partnership with WHO in the fight against Neglected Tropical diseases

10


NEGLECTED TROPICAL DISEASES

A genuine partner to fight and eliminate sleeping sickness by 2020.

OUR RESPONSIBILITY

IMPROVE ACCESS TO MEDICINES

WHO – February 2014

patients treated

175,000 Acting

ethically and

responsibly is part of our DNA

people were screened

27million

More than

SLEEPING SICKNESS

Access to healthcare for excluded populations

PRECARITY AND HEALTH

Ease and improve access

to healthcare for socially

excluded populations

in France through

a partnership with the Red

Cross, Médecins du Monde

and the Samu Social.


Maternal and infant mortality

STAND UP FOR AFRICAN MOTHERS

Initiated in 2010

in partnership with

the African Medical

& REsearch Foundation

(AMREF).

Today, 5 000 midwives

trained.

Childhood cancers in developing countries

MY CHILD MATTERS

45 projects in 33 countries in

Asia, Africa and Latin

America in partnership with

UICC (Union for International

Cancer Control)

OUR RESPONSIBILITY

REDUCING HEALTH INEQUALITIES

Sanofi’s commitment to protecting the safety of patients by fighting counterfeit medicines.

PROMOTE QUALITY HEALTHCARE

OUR RESPONSIBILITY


Laboratory dedicated to the analysis of counterfeit products

Sanofi mobile app for travelers on the dangers of counterfeit medicines.

https://itunes.apple.com/us/app/travel-tips-against-counterfeit/id771218216

products have been analysed

20,000

Supports market surveillance

* Since 2008

*

Apple, the Apple logo, iPad and iPhone are trademarks ofApple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.










KEY FIGURES 2013

Other countries

3,730 Emerging markets

10,957

United States

10,433

Western Europe

7,831

TOTAL SALES BY GEOGRAPHICAL ZONE (in million euros)

DETAIL OF GROWTH PLATFORMS (in million euros)

(Growth at constant exchange rates)


Emerging Markets €10,957M

Diabetes Solutions € 6,568M

Vaccines € 3,716M

Consumer Healthcare € 3,004M

Genzyme € 2,142M

Animal Health € 1,985M

Other Innovative Products € 705M

KEY FIGURES 2013

€32,951M


NET SALES (in million euros)

Our global workforce: more than 110,000 employees throughout the World

KEY FIGURES 2013


EMPLOYEES BY GEOGRAPHIC ZONE

Other countries

39,000

Europe

54,000

North America

18,000



82 sites pharmaceuticals

12 sites vaccines

17 sites animal health

* Information of December 31st 2013

112 Industrial sites*

in 41 countries, of which 37 are emerging countries

in Europe

in North America

in Asia

More than

20

R&D sites worldwide

PRESENT IN MORE THAN 100 COUNTRIES

KEY FIGURES 2013

CORPORATE PRESENTATION

2014

SANOFI India


SANOFI INDIA AT A GLANCE

DIVERSIFIED OFFERING

PRODUCTS

MANUFACTURING

CORPORATE SOCIAL RESPONSIBILITY

WORKING AT SANOFI

CONTENTS


OUR GROUP

SANOFI AT A GLANCE

Since 1956, Sanofi

has aligned itself with

India’s healthcare

needs by building

expertise, capability &

capacity, through continued

investments, strategic

partnerships, and a

shared commitment

towards patients.

exports to more than

30 countries

more than

5000 employees

3 state-of-the-art

manufacturing

sites

Operates through

5 legal entities

A

diversified

offering in Diabetes, Vaccines,

CHC, Animal Health

and innovative

therapeutic solutions

Present in India

since

1956 Evolved from Hoechst …

Aventis… sanofi-

aventis… to finally

Sanofi

through M&As

AT A GLANCE

SANOFI INDIA

OFFERS

THERAPEUTIC

SOLUTIONS

ACROSS…

ANTI-

INFECTIVES

NEPHROLOGY

VACCINES BIOSURGERY

ANIMAL

HEALTH

DIABETES

CARDIOVASCULAR

DISEASES

CENTRAL

NERVOUS SYSTEM

ONCOLOGY

CONSUMER

HEALTHCARE

MASS

THERAPY

RARE

DISEASES THROMBOSIS

CORPORATE PRESENTATION 2014

OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

DIVERSIFIED

OFFERING

SANOFI INDIA

34

OFFERS

THERAPEUTIC

SOLUTIONS

ACROSS…

ANTI-

INFECTIVES

NEPHROLOGY

VACCINES

BIOSURGERY

ANIMAL

HEALTH

DIABETES

CARDIOVASCULAR

DISEASES

CENTRAL

NERVOUS SYSTEM

ONCOLOGY CONSUMER

HEALTHCARE

MASS

THERAPY

RARE

DISEASES

THROMBOSIS


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

Sanofi Pasteur (the vaccines division of

Sanofi) offers protection

against

15 infectious

diseases

Genzyme – A Sanofi company:

Provides hope to Indian

patients with Rare

Diseases and creates

sustainable access

Consumer

Healthcare - an ensemble of more than

50 brands such as Seacod,

Combiflam, Primosa,

and Freeflex

Saath 7 Longest running

diabetes patient

support program

AllStar™ Indigenously

developed reusable

insulin pen specially

designed for Indian

patients

Diabetes

Merial creating a

healthier world

for animals

DIVERSIFIED

OFFERING

SANOFI INDIA

34


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

PRODUCTS

SANOFI INDIA Our top

10

brands*

*Source : IMS TSA Jan 2014

35

Group

Group

Group

Group

Group

Pharmaceuticals & Vaccines


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

MANUFACTURING

SANOFI INDIA

37

3 state-of-the-art

manufacturing sites

Ankleshwar

• Active Pharma

Ingredients (API)

• Formulations

Goa

• Formulation

production

• Formulation

development

Hyderabad

Vaccines

In 2013, manufactured…

8.5 bn units of

tablets and

capsules

145 mn units of vials

and

ampoules

34 mn units of

creams and

ointments

20 mn units of

liquids

For Domestic use

APIs, intermediates, granules,

bulk tablets and finished formulations

For exports


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

MANUFACTURING

SANOFI INDIA

38

Running Manufacturing

operations in India since

the last

54 years

India Manufacturing strengths

Technical experience

Ankleshwar

approved by

USFDA & AFFSAPS

Goa

approved by

European,

Australian, and

Brazilian regulatory

Facilities & systems

Production of API

Large volume

manufacturing

of formulations at own

sites

Effectively

managing huge

volumes

from external sites

Exports to 33

countries

Diverse expertise


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

CSR

SANOFI INDIA

39

OUR SUSTAINABILITY

APPROACH places the

patient at the ‘heart’ of

the way we conduct our

business.

OUR STRATEGY HAS

FOUR KEY AREAS:

Patient, Ethics, People

and Planet.


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

CSR

ACTIVITIES

SANOFI INDIA

40

REDUCING MATERNAL MORTALITY

Employees volunteer for

OPPI’s initiative to help

reduce Maternal Mortality in

India.

The employees have

participated in heath check-

up camps and have

reached out to more than

1000 mothers till date.

GYAN EXPRESS

An initiative to mentor

underprivileged children

in Mumbai, in association

with Concern India

Foundation.

Mentored 50 children from

4 NGOs in Mumbai over a

period of two months.

Employee volunteering

FUN CENTERS

Recreation zones,

created especially to

comfort and support the

little ones, as they cope

with the rigours of long

term treatment and

hospitalization

Sanofi ‘Fun Centers have

benefitted more than

30,000 children in 5

hospitals.

Patients

CSR

ACTIVITIES

SANOFI INDIA


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

CSR

ACTIVITIES

SANOFI INDIA

41

Health camps in schools

in partnership with the

Voluntary Health

Association of Goa

(VHAG).

8000 children monitored

and counselled through

these health camps, since

2012.

VHAG SEWA Rural

Blood sugar level testing

of the local community at

SEWA Rural hospital in

Ankleshwar.

More than 6,000 patients

benefitted from this service

since its launch in 2012.

Reducing health inequalities around sites

WINDMILL

A 2.1 MW offsite

windmill installed to

generate renewable

power at the Ankleshwar

manufacturing site,

through an agreement

with India’s largest wind

turbine manufacturer –

Suzlon Energy Limited

(SEL).

Planet

CSR

ACTIVITIES

SANOFI INDIA


OUR GROUP

SANOFI AT A GLANCE

DIVERSIFIED

OFFERING

SANOFI INDIA

WORKING AT

SANOFI

SANOFI INDIA

42

Acquire skills

and create

opportunities

Immense scope to

develop and

expand skill-sets

Take pride in

contributing to

world health

Strive for

excellence

to improve the

health of patients

around the world

Work with

committed

professionals

An environment

of mutual respect

where people

enjoy collaborating

and learning

from each other

AT SANOFI, OUR EMPLOYEES…

Ethics & Compliance Hallmark of everything we do

Further information:

www.sanofi.in

SANOFI CORPORATE COMMUNICATIONS

54-A, SIR MATHURADAS VASANJI ROAD,

ANDHERI – EAST,

MUMBAI 400 093

TEL: 022 28278000

Documents

SANOFI A global healthcare leader, focused on patients’ … contents corporate presentation 2014 2 sanofi at a glance our growth platforms innovation in r&d our responsibility key